<DOC>
	<DOCNO>NCT00369486</DOCNO>
	<brief_summary>The study involve enrollment patient 18 year age diabetic macular edema involve center macula already give maximal laser treatment . Patients one study eye randomly assign ( stratified prior laser ) equal probability one five treatment group : 1 . Focal laser photocoagulation ( modify ETDRS technique ) 2 . Posterior peribulbar injection 40 mg triamcinolone ( Kenalog ) 3 . Anterior peribulbar injection 20 mg triamcinolone 4 . Posterior peribulbar injection 40 mg triamcinolone follow one month laser 5 . Anterior peribulbar injection 20 mg triamcinolone follow one month laser For patient two study eye ( eye eligible time randomization ) , right eye ( stratified prior laser ) randomly assign equal probability one five treatment group list . If right eye assign laser , leave eye assign one four triamcinolone group equal probability ( stratified prior laser ) . If right eye assign receive triamcinolone , leave eye receive laser . Triamcinolone acetonide corticosteroid utilized study . The triamcinolone acetonide preparation use Kenalog . Kenalog manufacture Bristol Myers Squibb approve Food Drug Administration intramuscular use variety indication . Peribulbar injection Kenalog use wide variety ocular condition , particularly uveitis post-cataract extraction cystoid macular edema , many year . Two different triamcinolone regimen assess study : 40 mg inject posteriorly 20 mg inject anteriorly . There indication treatment regimen well . Although injection behind eye common injection near front eye , injection near front eye less risk injure eye . However , possible injection near front eye may increase eye pressure frequently . Little known two injection decrease macular edema improve vision often . Patients enrol study follow three year study visit 1 month , 2 month , 4 month , 8 month annually receive assign study treatment . For first 8 month study , patient retreat randomized treatment . However , patient 's visual acuity decrease 15 letter , treatment may give investigator 's discretion . After completion 8-month visit , treatment investigator discretion . The primary objective study obtain estimate efficacy safety outcome treatment group . These estimate provide basis sample size estimation hypothesis generation phase III trial .</brief_summary>
	<brief_title>A Pilot Study Peribulbar Triamcinolone Acetonide Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetic retinopathy major cause visual impairment United States . Diabetic macular edema ( DME ) manifestation diabetic retinopathy produce loss central vision . Data Wisconsin Epidemiologic Study Diabetic Retinopathy ( WESDR ) estimate 15 year know diabetes , prevalence diabetic macular edema approximately 20 % patient type 1 diabetes mellitus ( DM ) , 25 % patient type 2 DM take insulin , 14 % patient type 2 DM take insulin . Diabetic macular edema result abnormal leakage macromolecule , lipoprotein , retinal capillary extravascular space follow oncotic influx water extravascular space . Abnormalities retinal pigment epithelium may also cause contribute diabetic macular edema . These abnormality may allow increase fluid choriocapillaries enter retina may decrease normal efflux fluid retina choriocapillaris . The mechanism breakdown blood retina barrier level retinal capillary retinal pigment epithelium may due change tight junction protein occludin . The increase retinal capillary permeability subsequent retinal edema may result breakdown blood retina barrier mediate part vascular endothelial growth factor ( VEGF ) , 45 kD glycoprotein . Aiello et al , demonstrate vivo model VEGF increase vascular permeability . Fifteen eye 15 albino Sprague-Dawley rat receive intravitreal injection VEGF . The effect intravitreal administration VEGF retinal vascular permeability assess vitreous fluorophotometry . In 15 eye receive intravitreal injection VEGF , statistically significant increase vitreous fluorescein leakage record . In contrast , control eye , fellow eye inject vehicle alone , demonstrate statistically significant increase vitreous fluorescein leakage . Vitreous fluorescein leakage eye inject VEGF attain maximum 227 % control level . Antonetti et al , demonstrate VEGF may regulate vessel permeability increase phosphorylation tight junction protein occludin zonula occluden 1 . Sprague-Dawley rat give intravitreal injection VEGF change tight junction protein observe Western blot analysis . Treatment alkaline phosphatase reveal change cause change phosphorylation tight junction protein . This model provide , molecular level , potential mechanism VEGF-mediated vascular permeability eye . Similarly , human non-ocular disease state ascites , VEGF characterize potent vascular permeability factor ( VPF ) . The normal human retina contain little VEGF ; however , hypoxia cause upregulation VEGF production . Vinores et al , use immunohistochemical staining VEGF , demonstrate increase VEGF stain find retinal neuron retinal pigment epithelium human eye diabetic retinopathy . As discussion suggest , attenuation effect VEGF provide rationale treatment macular edema associate diabetic retinopathy . Corticosteroids , class substance anti-inflammatory property , demonstrate inhibit expression VEGF gene . In study Nauck et al , platelet-derived growth-factor ( PDGF ) induce expression VEGF gene culture human aortic vascular smooth muscle cell abolish corticosteroid dose-dependent manner . A separate study Nauck et al demonstrated corticosteroid abolish induction VEGF pro-inflammatory mediator PDGF platelet-activating factor ( PAF ) time dose-dependent manner . This study perform use primary culture human pulmonary fibroblast pulmonary vascular smooth muscle cell . As discussed , corticosteroid experimentally show regulate VEGF production possibly reduce breakdown blood-retinal barrier . Similarly , steroid anti-angiogenic property possibly due attenuation effect VEGF . Both steroid effect utilized . For example , triamcinolone acetonide often use clinically periocular injection treatment cystoid macular edema ( CME ) secondary uveitis result intraocular surgery . In animal study , intravitreal triamcinolone acetonide use prevention proliferative vitreoretinopathy retinal neovascularization . Intravitreal triamcinolone acetonide use clinically treatment proliferative vitreoretinopathy choroidal neovascularization .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Subject Level Criteria Inclusion To eligible , follow inclusion criterion ( 14 ) must meet : 1 . Age ≥18 year 2 . Diagnosis diabetes mellitus ( type 1 type 2 ) 3 . At least one eye meet study eye criterion 4 . Able willing provide inform consent . Study Level Exclusion Criteria A patient eligible follow exclusion criterion ( 513 ) present : 5 . History chronic renal failure require dialysis kidney transplant . 6 . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure glycemic control ) . Patients poor glycemic control , within last 4 month , initiate intensive insulin treatment ( pump multiple daily injection ) plan next 4 month enrol . 7 . Participation investigational trial within 30 day study entry involve treatment drug receive regulatory approval time study entry . 8 . Known allergy corticosteroid component delivery vehicle . 9 . History systemic ( e.g. , oral , IV , IM , epidural , bursal ) corticosteroid within 4 month prior randomization topical , rectal , inhaled corticosteroid current use 2 time per week . 10 . History steroidinduced intraocular pressure elevation require IOPlowering treatment either eye . 11 . Warfarin ( coumadin ) currently use . 12 . Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) . If blood pressure bring 180/110 antihypertensive treatment , patient become eligible . 13 . Patient expect move area clinical center area cover another clinical center next 8 month . The patient must least one eye meeting inclusion criterion ( ae ) none exclusion criterion ( ft ) list : Study Eye Inclusion Criteria 1 . Best correct electronic Early Treatment Diabetic Retinopathy Study ( EETDRS ) visual acuity score ≥69 letter ( i.e. , 20/40 good ) . 2 . Definite retinal thickening due diabetic macular edema base clinical exam . 3 . Retinal thickness Optical Coherence Tomography ( OCT ) central subfield measure 250 micron . 4 . Maximal laser already give investigator believe either peribulbar steroid laser may benefit eye ( note : subject may enrol without received prior macular laser ) . 5 . Media clarity , pupillary dilation , patient cooperation sufficient adequate fundus photograph OCT. Study Eye Exclusion Criteria 6 . Macular edema consider due cause diabetic macular edema . 7 . An ocular condition present , opinion investigator , visual acuity would improve resolution macular edema ( e.g. , foveal atrophy , pigmentary change , dense subfoveal hard exudate , nonretinal condition ) . 8 . An ocular condition present ( diabetes ) , opinion investigator , might affect macular edema alter visual acuity course study ( e.g. , vein occlusion , uveitis ocular inflammatory disease , neovascular glaucoma , IrvineGass Syndrome , etc. ) . 9 . History prior treatment intravitreal , peribulbar , retrobulbar corticosteroid DME . 10 . History focal/grid macular photocoagulation within 15 week ( 3.5 month ) prior randomization . Note : Patients require prior macular photocoagulation enrol . 11 . History panretinal scatter photocoagulation ( PRP ) within 4 month prior randomization anticipate need PRP 4 month follow randomization . m. History prior vitrectomy . n. History major ocular surgery ( include cataract extraction , scleral buckle , intraocular surgery , etc . ) within prior 6 month anticipate within next 6 month follow randomization . . History YAG capsulotomy perform within 2 month prior randomization . p. Intraocular pressure ≥25 mmHg . q . History openangle glaucoma ( either primary openangle glaucoma cause openangle glaucoma ; note : angleclosure glaucoma exclusion ) . A history ocular hypertension exclusion long ( 1 ) intraocular pressure &lt; 25 mm Hg , ( 2 ) patient use one topical glaucoma medication , ( 3 ) recent visual field , perform within last 12 month , normal ( abnormality present visual field must attributable patient 's diabetic retinopathy ) , ( 4 ) optic disc appear glaucomatous . Note : intraocular pressure 22 &lt; 25 mm Hg , criterion ocular hypertension eligibility must meet . r. History prior herpetic ocular infection . s. Exam evidence ocular toxoplasmosis . t. Exam evidence pseudoexfoliation . A patient may two `` study eye '' eligible time randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>diabetic</keyword>
	<keyword>macular</keyword>
	<keyword>edema</keyword>
	<keyword>peribulbar</keyword>
	<keyword>triamcinolone</keyword>
	<keyword>acetonide</keyword>
	<keyword>laser</keyword>
	<keyword>photocoagulation</keyword>
	<keyword>intraocular</keyword>
	<keyword>DME</keyword>
</DOC>